Questions answered
Ipamorelin, answered plainly and with sources
Direct answers to the questions people actually ask, each tied to the study behind it.
What does CJC-1295 and ipamorelin do?
Together they raise the body's own growth-hormone output through two different receptors at once — CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor — which produces a larger pulse than either alone. The synergy is established across the peptide family: combinations of a GHRH analog and a GHRP keep releasing growth hormone even under the somatostatin "stop" signal that blunts GHRH by itself [7][9].
How much CJC-1295 ipamorelin should I take?
No published controlled trial establishes a human dose for the combination, so no dose can be responsibly stated here. Single-agent CJC-1295 studies used 30 to 60 micrograms per kilogram subcutaneously [11], and ipamorelin's human exposure was characterized only intravenously [2], but the paired community regimens are anecdotal and untested. This digest reports doses from studies, never as personal protocols.
Does CJC-1295 ipamorelin work?
For raising growth-hormone output, the class-level evidence that a GHRH-analog-plus-GHRP combination outperforms either agent alone is solid [9][10]. For the popular promises — fat loss, muscle, anti-aging — there is no controlled human outcome trial of the combination, and ipamorelin's own single efficacy trial failed its endpoint [3]. So: likely raises growth hormone; the downstream benefits remain unproven.
Where to inject CJC-1295 ipamorelin?
Subcutaneous injection is the route community protocols use and the route most rodent body-composition studies of ipamorelin used [4], but this digest does not give injection-site or technique instructions — that is clinical guidance, not editorial summary. Note that ipamorelin's human data come from intravenous studies, not subcutaneous self-administration [2][3].
Can you take CJC-1295 ipamorelin and sermorelin together?
Mechanistically, CJC-1295 and sermorelin are both GHRH analogs working on the same receptor, so combining them adds two compounds doing the same job rather than complementary ones; the productive synergy is between a GHRH analog and a GHRP like ipamorelin [9][10]. No controlled human trial tests any of these three-way combinations, and this digest describes mechanism only, not a protocol.
Can you take tesamorelin and ipamorelin together?
Tesamorelin is a GHRH analog and ipamorelin is a ghrelin-receptor agonist, so the pairing follows the same complementary two-door logic as the CJC-1295 stack [9][10]. However, tesamorelin is an approved drug and ipamorelin is not [3], and no controlled trial has tested this specific combination. The mechanistic rationale exists; combination outcome evidence does not.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective ghrelin-receptor (GHS-R1a) agonist that releases growth hormone. Its 1998 characterization showed potent growth-hormone release in rat cells, rats and swine without raising cortisol even far above its growth-hormone threshold — the selectivity that defines it [1]. It has never been an approved drug.
What does ipamorelin do for you?
In studies, ipamorelin triggers a pulse of the body's own growth hormone by activating the ghrelin receptor [1]. Documented animal effects include dose-dependent long-bone growth in rats [4] and reduced chemotherapy weight loss in ferrets [5]. Its one human efficacy trial, for post-surgical bowel recovery, failed [3]. Community-reported effects like better sleep are anecdotal, not clinical.
What is ipamorelin peptide?
Ipamorelin peptide is the five-amino-acid molecule itself — a protease-resistant ghrelin mimic built from two mirror-image amino acids and one non-natural unit (Aib) to resist enzymatic breakdown [1]. It weighs about 712 daltons and was derived from the earlier peptide GHRP-1. Functionally it is a selective growth-hormone secretagogue [1].
What are the risks of ipamorelin?
The honest risk picture is dominated by the unknowns: no long-term human safety data exist. Documented concerns are mechanistic or class-level — growth-hormone-axis effects on blood sugar and IGF-1, and a chronic cardiac signal seen with a different ghrelin-receptor agonist in rats [6]. The one short human trial raised no ipamorelin-specific alarm but also showed no benefit [3].
Does ipamorelin reduce belly fat?
No human trial shows ipamorelin reduces belly fat. The closest evidence is a 2024 ferret study where it cut chemotherapy-driven weight loss by about 24 percent through a peripheral mechanism [5] — which is preserving weight, not targeting belly fat, and in animals. In mice it actually raised fat mass and leptin via a growth-hormone-independent route [16]. The fat-loss claim is not supported in humans.
What are the downsides of ipamorelin?
Beyond the absence of proven human benefit — its one efficacy trial failed [3] — the downsides are the open safety questions: no long-term human data, a class-level cardiac signal in rats [6], unpredictable blood-sugar effects by mechanism [18], and unverified purity of gray-market research material [3]. Community-reported nuisance effects include flushing and injection-site reactions, all anecdotal.
Why is ipamorelin being discontinued?
Ipamorelin's clinical development effectively ended when its only Phase 2 trial, for postoperative ileus, missed its primary endpoint and no Phase 3 followed [3]. On the regulatory side, in 2024 the FDA removed ipamorelin acetate from the interim Section 503A Category 2 bulk-substances list and reviewed it at an October 2024 advisory-committee meeting, tightening compounding-pharmacy access. The story is a stalled program, not a safety recall.
Does ipamorelin increase IGF-1?
Not consistently in short studies. The rat long-bone-growth study found dose-dependent skeletal growth with no measurable change in total IGF-1, suggesting a partly local, pulse-driven effect [4]. Sustained protocols would be expected to raise IGF-1 downstream of growth hormone, but ipamorelin-specific human IGF-1 data are lacking. The honest answer is: probably over time, but the short-term rodent data did not show it [4].
How does CJC-1295 ipamorelin work?
CJC-1295 activates the GHRH receptor and ipamorelin activates the ghrelin receptor; the two pathways are complementary, so together they release more growth hormone than either alone and better overcome the body's somatostatin "stop" signal [7][12]. Endogenous GHRH is actually required for ipamorelin to work fully [9], which is why pairing it with a GHRH analog is mechanistically logical [10].
How to reconstitute CJC-1295 ipamorelin 5mg?
Ipamorelin is supplied as a lyophilized (freeze-dried) powder reconstituted with bacteriostatic water for research handling, and as a peptide it is kept refrigerated and protected from repeated freeze-thaw [2]. This digest gives general handling context only, not a step-by-step mixing or dosing protocol — preparation instructions are clinical guidance outside an editorial summary of the science.
How long does ipamorelin stay in your system?
Ipamorelin's terminal half-life in healthy human volunteers is approximately two hours after intravenous dosing, with clearance of 0.078 L/h/kg [2]. The growth-hormone pulse it produces peaks around forty minutes post-dose and then subsides [2]. As a growth-hormone secretagogue it is also detectable in urine by accredited anti-doping laboratories, which is the basis of its WADA-prohibited enforcement.
Does ipamorelin make you hungry?
It can, by mechanism. Ipamorelin is a ghrelin-receptor agonist, and ghrelin is the body's appetite signal — central activation of that system induces feeding in animals [17]. Increased hunger after a dose is occasionally reported by users, generally described as milder than with GHRP-6 [16]. It is plausible and reported, though it varies by individual and is not universal.
Will I gain weight on ipamorelin?
In mice, ipamorelin produced a small body-weight increase with raised fat-pad weight and leptin, partly independent of growth hormone [16]. In a ferret cachexia model it preserved weight against chemotherapy [5]. Human weight data are absent, and its one human trial measured bowel recovery, not body weight [3]. Any weight change in practice would be confounded by diet and training; the anecdotal reports are mixed.
Does ipamorelin increase appetite?
By mechanism, yes — as a ghrelin-receptor agonist it engages the same appetite-driving system the natural hunger hormone uses, and central ghrelin/secretagogue administration activates brain appetite centers in animals [17]. The mouse data showing raised food intake and adiposity reinforce a class-level orexigenic effect [16]. Users report this as occasional and generally milder than older peptides, but it is a genuine, mechanism-based effect.
What does ipamorelin peptide do?
Ipamorelin peptide selectively activates the ghrelin receptor to release a pulse of the body's own growth hormone, without meaningfully raising cortisol or prolactin [1]. In animals it has produced dose-dependent long-bone growth [4] and reduced chemotherapy-associated weight loss [5]. In its one human efficacy trial it did not work [3]. It is a research compound, not an approved medicine.
How long does it take for ipamorelin to work?
Pharmacologically, ipamorelin acts fast: the growth-hormone pulse peaks around forty minutes after an intravenous dose [2]. Perceived effects are a separate question with no controlled-trial answer — community accounts describe sleep changes within the first week or two, but those are anecdotal and unverified. The measured hormonal action is rapid; any subjective "working" timeline is not established in humans [2].